All News

FDA.approved.jpg

FDA Approves Icotrokinra for Plaque Psoriasis

Jack Cush, MD

Today the FDA approved an oral IL-23 inhibitor, icotrokinra (Icotyde), for use in moderate-to-severe plaque psoriasis in adults and children 12 years of age and older (who weigh at least 40 kg) who are candidates for systemic therapy or phototherapy.

Read Article
purpura

Hydralazine and the Rare Risk of Vasculitis

Jack Cush, MD

Since the 1980s, hydralazine has been a notable cause of drug-induced lupus, and inferred to cause vasculitis as well.

Read Article
guidelines.jpg (keep)

2025 Update: EULAR Recommendations on Rheumatoid Arthritis Management

Jack Cush, MD

The European Alliance of Associations for Rheumatology (EULAR) has updated their rheumatoid arthritis (RA) management recommendations, notably with fewer recommendations (total of 9, down from 11 in 2022 version), by merging and removing previous recommendations.

Read Article
uricacid.jpg

Worldwide Trends in Hyperuricemia

Jack Cush, MD

A Lancet Rheumatology systematic review shows the prevalence of hyperuricaemia has risen markedly over the past two decades in both men and women, owing to population growth, aging, and increasing age-specific rates

Read Article
RheumNow Podcast square

Poets Know It (3.13.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, regulatory decisions and new journal articles.

Read Article
Screen%20Shot%202018-11-01%20at%2010.14.03%20AM_0.png

Rheumatic Immune-related Adverse Effects with Checkpoint Inhibitor Therapy

Jack Cush, MD

A retrospective study of patients who developed rheumatic immune-related adverse events (R-irAEs) after receiving immune checkpoint inhibitors (ICIs) at two oncology centers in Spain suggests that early recognition can lead to effective management that allows continuation of cancer therapy. 

Read Article
RA erosions bone ACR

b/ts-DMARDs Do Not Arrest Bone Loss in RA

Jack Cush, MD

In RA, the goal is to control or arrest inflammation such that articular and bony damage is halted. While we have many effective therapies, it is not clear that biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) can prevent or improve osteoporosis outcomes in RA. A current real-world study showed that 1 year of b/tsDMARDs use did not arrest osteoporosis progression.

Read Article
antibody (Keep)

NEJM: Obinutuzumab in Active Systemic Lupus Erythematosus

Jack Cush, MD

A phase 3 trial of obinutuzumab, an anti-CD20 monoclonal antibody, showed potent B-cell depletion and clinical efficacy active systemic lupus erythematosus without evidence of nephritis.

Read Article
Eye exam 2

Long-Term Hydroxychloroquine Retinopathy Risk

MedPage Today

About one in 18 patients taking hydroxychloroquine (HCQ) for 15 years develop retinal damage, a new meta-analysis indicated.

Read Article
FDA%20approved.jpg (keep)

TYK2 Inhibitor Deucravacitinib FDA Approved for Psoriatic Arthritis

Jack Cush, MD

On Friday, March 6th, the FDA approved deucravacitinib (Sotyktu) for the treatment of adults with active psoriatic arthritis (PsA) based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials.

Read Article
REVEAL, a 5-yr real-world study of 236 SLE pts initiating anifrolumab (basekbube SLEDAI-2K 7 for mucocutaneous (67%) & MSK (49%) dz. At 6 months, 26% achieved remission, 66% reached LLDAS, and 57% achieved LLDAS5. Authors claim rapid onset of action https://t.co/16OQatOcPj https://t.co/YmS2dRolL1

Links:

Dr. John Cush RheumNow ( View Tweet)
Managing Gout in CKD Patients A current review article addressed the management of gout patients with chronic kidney disease (CKD). This full read review addresses the epidemiology, challenges, treatment decisions, and outcomes. https://t.co/ND0cspcmDd https://t.co/HI55D5koZj

Links:

Dr. John Cush RheumNow ( View Tweet)
Long-Term Hydroxychloroquine Retinopathy Risk About one in 18 patients taking hydroxychloroquine (HCQ) for 15 years develop retinal damage, a new meta-analysis indicated. https://t.co/TBSTIb29Pf https://t.co/7TYQe4N4JH

Links:

Dr. John Cush RheumNow ( View Tweet)
The Role of Calcineurin Inhibitors in Lupus Nephritis In the U.S, lupus nephritis affects approximately 40–50% of patients with systemic lupus erythematosus (SLE), contributing significantly to the morbidity and mortality of the affected individuals (1). However, significant https://t.co/sc4cgAYzGy
Dr. John Cush RheumNow ( View Tweet)
Sodium-glucose cotransporter-2 (SGLT2) inhibitors lower serum uric acid levels, by approximately 0.6 to 1.5 mg/dL. They increase renal uric acid excretion via a uricosuric effect), thereby reducing gout risk by 30% to 50%. https://t.co/weXVOhpiP9 https://t.co/NsCRNi9JI9

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of calcineurin inhib. in RA - 11 RCTs, 1793 RA pts. Cyclosporin (CSA( (RR 1.6 & Tacrolimus (TAC (RR 2.1) signif improved ACR20 responses. CSA was dose dependent, less so w/ TAC. Both require serum Creat. monitoring consistent increase in s-Cr https://t.co/OxNGYbupnt https://t.co/F08vDCMYtr

Links:

Dr. John Cush RheumNow ( View Tweet)
Long-Term Hydroxychloroquine Retinopathy Risk About one in 18 patients taking hydroxychloroquine (HCQ) for 15 years develop retinal damage, a new meta-analysis indicated. https://t.co/Gp6o0FfEYA https://t.co/TjLNXl229v

Links:

Dr. John Cush RheumNow ( View Tweet)
Basic, full-read overview of "JAK inhibitors: risks and safety principles" from the Pharmaceutical Journal. Addresses MOA, indications, warnings, monitoring, adverse effects, interactions, Serious AEs, vaccination and best practices. https://t.co/qrqeu1CzRg https://t.co/7qIszLwUrf

Links:

Dr. John Cush RheumNow ( View Tweet)
The Role of Calcineurin Inhibitors in Lupus Nephritis In the U.S, lupus nephritis affects approximately 40–50% of patients with systemic lupus erythematosus (SLE), contributing significantly to the morbidity and mortality of the affected individuals (1). However, significant https://t.co/JBz0gQeJUr
Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine Lowers SLE and RA Hospitalizations A population-based study from British Columbia, Canada, shows that antimalarial adherence was associated with a lower risk of hospital admission in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus https://t.co/vsJDOh09ji
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×